165 related articles for article (PubMed ID: 36930735)
1. Transcriptomic Profiling Reveals Chemokine CXCL1 as a Mediator for Neutrophil Recruitment Associated With Blood-Retinal Barrier Alteration in Diabetic Retinopathy.
Monickaraj F; Acosta G; Cabrera AP; Das A
Diabetes; 2023 Jun; 72(6):781-794. PubMed ID: 36930735
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomics analysis of pericytes from retinas of diabetic animals reveals novel genes and molecular pathways relevant to blood-retinal barrier alterations in diabetic retinopathy.
Rangasamy S; Monickaraj F; Legendre C; Cabrera AP; Llaci L; Bilagody C; McGuire P; Das A
Exp Eye Res; 2020 Jun; 195():108043. PubMed ID: 32376470
[TBL] [Abstract][Full Text] [Related]
3. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy.
Rangasamy S; McGuire PG; Franco Nitta C; Monickaraj F; Oruganti SR; Das A
PLoS One; 2014; 9(10):e108508. PubMed ID: 25329075
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin D: an Mϕ-derived factor mediating increased endothelial cell permeability with implications for alteration of the blood-retinal barrier in diabetic retinopathy.
Monickaraj F; McGuire PG; Nitta CF; Ghosh K; Das A
FASEB J; 2016 Apr; 30(4):1670-82. PubMed ID: 26718887
[TBL] [Abstract][Full Text] [Related]
5. Photoreceptor cells produce inflammatory products that contribute to retinal vascular permeability in a mouse model of diabetes.
Tonade D; Liu H; Palczewski K; Kern TS
Diabetologia; 2017 Oct; 60(10):2111-2120. PubMed ID: 28755268
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil elastase contributes to the pathological vascular permeability characteristic of diabetic retinopathy.
Liu H; Lessieur EM; Saadane A; Lindstrom SI; Taylor PR; Kern TS
Diabetologia; 2019 Dec; 62(12):2365-2374. PubMed ID: 31612267
[TBL] [Abstract][Full Text] [Related]
7. Characterization of azurocidin as a permeability factor in the retina: involvement in VEGF-induced and early diabetic blood-retinal barrier breakdown.
Skondra D; Noda K; Almulki L; Tayyari F; Frimmel S; Nakazawa T; Kim IK; Zandi S; Thomas KL; Miller JW; Gragoudas ES; Hafezi-Moghadam A
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):726-31. PubMed ID: 18235021
[TBL] [Abstract][Full Text] [Related]
8. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis.
Huang H; Gandhi JK; Zhong X; Wei Y; Gong J; Duh EJ; Vinores SA
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1336-44. PubMed ID: 21212173
[TBL] [Abstract][Full Text] [Related]
9. A potential novel therapeutic target in diabetic retinopathy: a chemokine receptor (CCR2/CCR5) inhibitor reduces retinal vascular leakage in an animal model.
Monickaraj F; Oruganti SR; McGuire P; Das A
Graefes Arch Clin Exp Ophthalmol; 2021 Jan; 259(1):93-100. PubMed ID: 32816099
[TBL] [Abstract][Full Text] [Related]
10. Α-Melanocyte-Stimulating Hormone Protects Early Diabetic Retina from Blood-Retinal Barrier Breakdown and Vascular Leakage via MC4R.
Cai S; Yang Q; Hou M; Han Q; Zhang H; Wang J; Qi C; Bo Q; Ru Y; Yang W; Gu Z; Wei R; Cao Y; Li X; Zhang Y
Cell Physiol Biochem; 2018; 45(2):505-522. PubMed ID: 29402864
[TBL] [Abstract][Full Text] [Related]
11. MyD88-dependent pathways in leukocytes affect the retina in diabetes.
Tang J; Allen Lee C; Du Y; Sun Y; Pearlman E; Sheibani N; Kern TS
PLoS One; 2013; 8(7):e68871. PubMed ID: 23874797
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy.
Wisniewska-Kruk J; Klaassen I; Vogels IM; Magno AL; Lai CM; Van Noorden CJ; Schlingemann RO; Rakoczy EP
Exp Eye Res; 2014 May; 122():123-31. PubMed ID: 24703908
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models.
Ting KK; Zhao Y; Shen W; Coleman P; Yam M; Chan-Ling T; Li J; Moller T; Gillies M; Vadas MA; Gamble JR
Diabetologia; 2019 Feb; 62(2):322-334. PubMed ID: 30443753
[TBL] [Abstract][Full Text] [Related]
14. Cellular communication network factor 1 promotes retinal leakage in diabetic retinopathy via inducing neutrophil stasis and neutrophil extracellular traps extrusion.
Li T; Qian Y; Li H; Wang T; Jiang Q; Wang Y; Zhu Y; Li S; He X; Shi G; Su W; Lu Y; Chen Y
Cell Commun Signal; 2024 May; 22(1):275. PubMed ID: 38755602
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway.
Elshaer SL; Alwhaibi A; Mohamed R; Lemtalsi T; Coucha M; Longo FM; El-Remessy AB
Diabetologia; 2019 Aug; 62(8):1488-1500. PubMed ID: 31073629
[TBL] [Abstract][Full Text] [Related]
16. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy.
Kim JH; Kim JH; Yu YS; Cho CS; Kim KW
J Cereb Blood Flow Metab; 2009 Mar; 29(3):621-8. PubMed ID: 19107135
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor ligand-related molecule 1A maintains blood-retinal barrier via modulating SHP-1-Src-VE-cadherin signaling in diabetic retinopathy.
Li J; Xie R; Jiang F; Li Y; Zhu Y; Liu Z; Liao M; Liu Y; Meng X; Chen S; Yu J; Du M; Wang X; Chen Y; Yan H
FASEB J; 2021 Nov; 35(11):e22008. PubMed ID: 34679191
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemia Induces Mitochondrial Reactive Oxygen Species Production Through Increased Fatty Acid Oxidation and Promotes Retinal Vascular Permeability in Diabetic Mice.
Yoshinaga A; Kajihara N; Kukidome D; Motoshima H; Matsumura T; Nishikawa T; Araki E
Antioxid Redox Signal; 2021 Jun; 34(16):1245-1259. PubMed ID: 32757614
[No Abstract] [Full Text] [Related]
19. Decreased lysyl oxidase level protects against development of retinal vascular lesions in diabetic retinopathy.
Kim D; Mecham RP; Nguyen NH; Roy S
Exp Eye Res; 2019 Jul; 184():221-226. PubMed ID: 31022398
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin maintains VE-cadherin expression and barrier function in experimental diabetic retinopathy via inhibiting VEGF/VEGFR2/Src signaling pathway.
Liu D; Xu H; Zhang C; Xie H; Yang Q; Li W; Tian H; Lu L; Xu JY; Xu G; Liu K; Sun X; Xu GT; Zhang J
Life Sci; 2020 Oct; 259():118273. PubMed ID: 32800831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
